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Background
A central concept for the development of an effective HIV
vaccine that induces T-cell responses is coverage – the
extent to which reactive epitopes in vaccinees are repre-
sented in circulating viruses to which the vaccinees will be
exposed.
Methods
We developed a model for epitope coverage of a target
viral population by a T-cell vaccine that expresses coverage
as a function of breadth of response (number of epitopes
recognized) and the frequency with which vaccine-
induced epitope responses are represented in the targeted
viral population. This model was used to analyze epitope
mapping data from 2 study populations: participants who
received the Merck Ad5 HIV vaccine (insert: clade B gag,
pol, nef) and participants who received the VRC multi-
gene Ad5 HIV vaccine (insert: clade B gag-pol and clades
A, B, C env).
Results
Results from these analyses include: 1) Recipients of the
Merck vaccine demonstrated limited breadth in their
CD8+ T cell responses to subtype B HIV (median 2
epitopes per vaccineee). These responses were infre-
quently directed against the most highly conserved por-
tions of the gag or nef genes, despite the inclusion of these
regions in the vaccine insert. The resultant low coverage
may have been a primary factor underlying lack of efficacy
seen in the Step trial; 2) Our analyses indicate that increas-
ing breadth of response has greater potential to improve
coverage than shifting the set of reactive epitopes to more
conserved specificities.
Conclusion
We suggest that epitope mapping data be obtained rou-
tinely in early phase clinical evaluation of T-cell HIV vac-
cine candidates and that an analysis of coverage be
explicitly considered in the decision to advance the candi-
date to efficacy evaluation. We also recommend that
increased emphasis be placed on developing vaccine
designs that increase breadth of response.
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